Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-Dansyl-PSMA in mCRPC
NCT06377683Phase 1Completed
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-LNC1011 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: Incidence of treatment-related adverse events (safety and tolerability) and Maximum Tolerated Dose (MTD). Started Apr 2024; status: completed.
02
Drugs
177Lu-LNC1011
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06377683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06377683.